“Because it’s a living organism, we can engineer our tularemia vaccine to produce 'pieces' of the SARS CoV-2 virus, which will allow the host to recognize it and make antibodies against it," said Karl Klose, a UTSA microbiology professor and director of the South Texas Center for Emerging Infectious Diseases. "We hope that these antibodies will protect people against COVID-19, in addition to tularemia."San Antonio Partnership for Precision Therapeutics issued a call for COVID-19 funding proposals shortly after the coronavirus swept into Texas. Within a week, it received 17 and ultimately selected the UTSA consortium for the grant.
San Antonio Current works for you, and your support is essential.
Our small but mighty local team works tirelessly to bring you high-quality, uncensored news and cultural coverage of San Antonio and beyond.
Unlike many newspapers, ours is free – and we'd like to keep it that way, because we believe, now more than ever, everyone deserves access to accurate, independent coverage of their community.
Whether it's a one-time acknowledgement of this article or an ongoing pledge, your support helps keep San Antonio's true free press free.